X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SMT112 (ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
SMT112 (Ivonescimab) is a potential first-in-class investigational PD-1/VEGF bi-specific antibody, which is investigated for the treatment of first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
SMT112 (ivonescimab) is an investigational bispecific antibody which blocks PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. It is being investigated for EGFR mutated NSCLC.
Lead Product(s): Ivonescimab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
SMT112 (ivonescimab) is a novel, potential first-in-class, investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.
Lead Product(s): Ivonescimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
The net proceeds will be used to support the development of SMT112. Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody. Engineered with Tetrabody technology, ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors.
Lead Product(s): Ivonescimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 03, 2023
Details:
The net proceeds will be used to support the development of SMT112. Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody. Engineered with Tetrabody technology, ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors.
Lead Product(s): Ivonescimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 30, 2023
Details:
Under the terms of agreement, Summit will receive the rights to develop and commercialize SMT112/AK112 (ivonescimab), a novel, potential first-in-class bispecific antibody, in the U.S.A, Canada, Europe, and Japan and Akeso will retain rights for the rest of the world.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: $5,000.0 million Upfront Cash: $500.0 million
Deal Type: Licensing Agreement January 20, 2023
Details:
Akeso out-license to Summit Therapeutics exclusive rights to SMT112 (ivonescimab) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso will retain development and commercialization rights for the rest of the world including China.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: $5,000.0 million Upfront Cash: $500.0 million
Deal Type: Collaboration January 20, 2023
Details:
Akeso to out-license to Summit Therapeutics exclusive rights to SMT112 (ivonescimab) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso will retain development and commercialization rights for the rest of the world including China.
Lead Product(s): Ivonescimab
Therapeutic Area: Oncology Product Name: SMT112
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Akeso
Deal Size: $5,000.0 million Upfront Cash: $500.0 million
Deal Type: Collaboration December 06, 2022
Details:
SMT19969 (ridinilazole) is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence.
Lead Product(s): Ridinilazole
Therapeutic Area: Infections and Infectious Diseases Product Name: SMT19969
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
